622
Participants
Start Date
March 31, 2011
Primary Completion Date
January 31, 2012
Study Completion Date
January 31, 2012
Tapentadol Prolonged Release
100 - 500 mg per day orally twice daily for a maximum of 12 weeks
Tapentadol Prolonged Release with Pregabalin
Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
Tapentadol Prolonged Release open label maintenance
100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
DE 118, Berlin
Site 506, Klagenfurt
Site 503, Senftenberg
Site 501, Vienna
Site 502, Vienna
Site 504, Vienna
Site 505, Vienna
Site 605, Dour
Site 602, Genk
Site 603, Gozée
Site 604, Ham
Site 601, Pellenberg
Site 702, Copenhagen
Site 704, Frederiksberg
Site 701, Glostrup Municipality
Site 703, Ringsted
Site 107, Berlin
Site 111, Böhlen
Site 105, Cologne
Site 116, Cologne
Site 115, Cottbus
Site 103, Hamburg
Site 110, Hamburg
Site 101, Kiel
Site 114, Kiel
Site 113, Leipzig
Site 109, Lübeck
Site 106, Rendsburg
Site 108, Schönau
Site 117, Weimar
Site 112, Westerstede
Site 104, Wiesbaden
Site 803, Amsterdam
Site 804, Eindhoven
Site 805, Enschede
Site 802, Heerenveen
Site 801, Sliedrecht
Site 309, Bydgoszcz
Site 312, Gdansk
Site 303, Katowice
Site 308, Krakow
Site 310, Krakow
Site 311, Krakow
Site 307, Lublin
Site 306, Ostrów Mazowiecka
Site 304, Poznan
Site 301, Warsaw
Site 302, Warsaw
Site 305, Wroclaw
Site 904, A Coruña
Site 908, Alicante
Site 901, Badalona
Site 905, Barcelona
Site 902, Centelles
Site 907, Granada
Site 909, Madrid
Site 910, Madrid
Site 903, Oviedo
Site 911, Valencia
Lead Sponsor
Grünenthal GmbH
INDUSTRY